Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 53 72 49
Endometriosis of Uterus 69

Characteristics:

OMIM:

53
Inheritance:
autosomal vs. x-linked dominant


Classifications:



External Ids:

OMIM 53 600458
MedGen 39 C0341858

Summaries for Adenomyosis

NIH Rare Diseases : 49 Adenomyosis is a rare condition that affects the uterus. In affected women, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended. Last updated: 3/15/2017

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to adenosarcoma and endometrial adenocarcinoma, and has symptoms including abnormality of the genitourinary system, abnormal bleeding and dysmenorrhea. An important gene associated with Adenomyosis is MMP2 (Matrix Metallopeptidase 2), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, endothelial and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

OMIM : 53 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 72 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 adenosarcoma 30.4 ESR1 PGR
2 endometrial adenocarcinoma 30.3 ESR1 PGR VEGFA
3 endometriosis 30.2 ESR1 MMP2 PGR PTGS2 VEGFA
4 endometriosis of ovary 29.9 ESR1 PGR
5 leiomyoma, uterine 29.9 ESR1 MMP1 MMP2 PGR
6 ovarian cyst 29.9 PRL VEGFA
7 endometrial stromal sarcoma 29.5 ESR1 MMP2 MMP9 OXTR PGR
8 endometrial cancer 29.4 ESR1 MMP2 MMP9 PGR TIMP2 VEGFA
9 breast cancer 26.0 ESR1 MMP1 MMP2 MMP9 PGR PRL
10 endometriosis of uterus 11.5
11 uterine anomalies 11.3
12 extracranial arteriovenous malformation 10.5 MMP2 MMP9
13 vulvar syringoma 10.5 ESR1 PGR
14 vestibular gland benign neoplasm 10.5 ESR1 PGR
15 lung leiomyoma 10.5 ESR1 PGR
16 bartholin's gland adenoma 10.5 ESR1 PGR
17 focal myositis 10.5 MMP2 MMP9
18 glassy cell carcinoma of the cervix 10.5 ESR1 PGR
19 vulvar benign neoplasm 10.5 ESR1 PGR
20 trigonitis 10.5 ESR1 PGR
21 vulvar leiomyoma 10.5 ESR1 PGR
22 lentigo maligna melanoma 10.5 MMP2 MMP9
23 villous adenocarcinoma 10.5 MMP2 MMP9
24 predominantly cortical thymoma 10.5 ESR1 PGR
25 psammomatous meningioma 10.5 MMP2 MMP9
26 breast medullary carcinoma 10.5 ESR1 PGR
27 acute transverse myelitis 10.5 MMP2 MMP9
28 breast scirrhous carcinoma 10.5 ESR1 PGR
29 angiokeratoma circumscriptum 10.5 MMP9 VEGFA
30 progesterone resistance 10.5 ESR1 PGR
31 progesterone-receptor positive breast cancer 10.5 ESR1 PGR
32 senile ectropion 10.5 MMP2 MMP9
33 cribriform carcinoma 10.5 ESR1 PGR
34 oncocytic breast carcinoma 10.5 ESR1 PGR
35 pancreatic serous cystadenoma 10.5 PGR VEGFA
36 bartholin's gland benign neoplasm 10.5 ESR1 PGR
37 endometrial squamous cell carcinoma 10.5 ESR1 PGR
38 gastric signet ring cell adenocarcinoma 10.5 ESR1 PGR
39 endometrial mucinous adenocarcinoma 10.5 ESR1 PGR
40 sick building syndrome 10.5 MMP9 VEGFA
41 adenoid basal cell carcinoma 10.4 ESR1 PGR
42 deep angioma 10.4 ESR1 PGR
43 apocrine adenocarcinoma 10.4 ESR1 PGR
44 gender identity disorder 10.4 ESR1 PGR
45 cervical carcinosarcoma 10.4 ESR1 PGR
46 synchronous bilateral breast carcinoma 10.4 ESR1 PGR
47 parotitis 10.4 MMP2 MMP9
48 breast adenoid cystic carcinoma 10.4 ESR1 PGR
49 adamantinous craniopharyngioma 10.4 MMP9 VEGFA
50 intramuscular hemangioma 10.4 ESR1 PGR

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Symptoms via clinical synopsis from OMIM:

53
GU:
adenomyosis

Lab:
endometrial glands and stroma within the myometrium
abnormal uterine bleeding
dysmenorrhea


Clinical features from OMIM:

600458

Human phenotypes related to Adenomyosis:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 31 HP:0000119
2 abnormal bleeding 31 HP:0001892
3 dysmenorrhea 31 HP:0100607

MGI Mouse Phenotypes related to Adenomyosis:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 PTGS2 SPP1 TIMP2 VEGFA ESR1 MMP9
2 homeostasis/metabolism MP:0005376 10.24 ESR1 MMP1 MMP2 MMP9 NGF PGR
3 cardiovascular system MP:0005385 10.18 ESR1 MMP2 MMP9 NGF PGR PTGS2
4 immune system MP:0005387 10.18 ESR1 TIMP2 MMP1 VEGFA MMP2 MMP9
5 hematopoietic system MP:0005397 10.11 ESR1 MMP2 MMP9 PGR PTGS2 SPP1
6 integument MP:0010771 10.11 ESR1 MMP9 NGF OXTR PGR PRL
7 muscle MP:0005369 10.09 SPP1 VEGFA ESR1 MMP2 MMP9 NGF
8 nervous system MP:0003631 10.07 ESR1 MMP2 MMP9 NGF OXTR PRL
9 neoplasm MP:0002006 10.06 ESR1 MMP1 MMP2 MMP9 PGR PRL
10 normal MP:0002873 9.86 OXTR PGR PTGS2 TIMP2 VEGFA ESR1
11 no phenotypic analysis MP:0003012 9.8 ESR1 NGF OXTR PGR PTGS2 VEGFA
12 reproductive system MP:0005389 9.76 ESR1 MMP9 OXTR PGR PRL PTGS2
13 respiratory system MP:0005388 9.43 ESR1 MMP2 MMP9 PTGS2 SPP1 VEGFA
14 skeleton MP:0005390 9.17 PTGS2 SPP1 VEGFA ESR1 MMP2 MMP9

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
5 Analgesics Phase 4,Phase 3
6 Cyclooxygenase Inhibitors Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Anti-Inflammatory Agents Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Antipyretics Phase 4
11 Antirheumatic Agents Phase 4
12 Ramosetron Approved, Investigational Phase 3 132036-88-5
13
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
14
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
15
Lactitol Investigational Phase 2, Phase 3 585-86-4 3871
16
Serotonin Phase 3 50-67-9 5202
17 Serotonin Agents Phase 3
18 Serotonin Antagonists Phase 3
19 Gastrointestinal Agents Phase 3
20 Neurotransmitter Agents Phase 3,Phase 1
21 Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
22 Hormones Phase 2, Phase 3,Phase 1,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
24 Antiemetics Phase 3
25 Estrogens Phase 2, Phase 3,Early Phase 1
26 Autonomic Agents Phase 3
27 Steroid Synthesis Inhibitors Phase 2, Phase 3
28 Estrogen Antagonists Phase 2, Phase 3
29 Antineoplastic Agents, Hormonal Phase 2, Phase 3
30 Aromatase Inhibitors Phase 2, Phase 3
31 Micronutrients Phase 3
32 Trace Elements Phase 3
33
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1 797-63-7, 17489-40-6 13109
34
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
35
Ropivacaine Approved Phase 2 84057-95-4 175805 71273
36 Contraceptive Agents Phase 2,Early Phase 1
37 Contraceptives, Oral Phase 2,Early Phase 1
38 Contraceptives, Oral, Combined Phase 2,Early Phase 1
39 Central Nervous System Depressants Phase 2
40 Sodium Channel Blockers Phase 2
41 Anesthetics Phase 2
42 Anesthetics, Local Phase 2
43 Diuretics, Potassium Sparing Phase 2,Early Phase 1
44 Anti-Arrhythmia Agents Phase 2
45
Dopamine Approved Phase 1 51-61-6, 62-31-7 681
46
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
47 Dopamine agonists Phase 1
48 Dopamine Agents Phase 1
49 Antiparkinson Agents Phase 1
50
Estradiol Approved, Investigational, Vet_approved Early Phase 1 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 54)

# Name Status NCT ID Phase Drugs
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;IV Placebo
2 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
3 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
4 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
5 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
6 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
7 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
8 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
9 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471 Phase 3
10 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Active, not recruiting NCT02437175 Phase 3
11 LNG-IUS for Treatment of Dysmenorrhea Completed NCT01601366 Phase 2 Combined oral contraceptives
12 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
13 Superior Hypogastric Nerve Block for Pain Control Post-UFE Completed NCT02270255 Phase 2 0.75% Ropivacaine;1% Xylocaine
14 Adenomyosis and Ulipristal Acetate Recruiting NCT02587000 Phase 2 Ulipristal acetate;Placebo
15 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
16 Vaginal Bromocriptine for Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
17 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180
18 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
19 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
20 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
21 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
22 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
23 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
24 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
25 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314
26 Histopathological Diagnosis of Adenomyosis Completed NCT02340533
27 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
28 Norwegian Adenomyosis Study I Completed NCT02201719
29 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309
30 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
31 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline
32 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606
33 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012
34 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279 GnRH analogue
35 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Completed NCT01793584
36 Electronic Catheter Stethoscope Completed NCT01463462
37 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501
38 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
39 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Recruiting NCT03037944 Early Phase 1 Yasmin
40 A Prospective Study of Diagnostic Accuracy of Ultrasound Recruiting NCT03120078
41 Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Recruiting NCT03302468
42 Cooperative Adenomyosis Network Recruiting NCT03230994
43 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704
44 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Recruiting NCT02086344
45 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Recruiting NCT03006406 Long term GnRH-a (3.75mg)
46 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Recruiting NCT03121560
47 Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Active, not recruiting NCT02197923
48 Norwegian Adenomyosis Study III: Peristalsis Active, not recruiting NCT02197936
49 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Active, not recruiting NCT01992718 Early Phase 1
50 Effect of Salpingectomy During Conservative Hysterectomy Active, not recruiting NCT01628432

Search NIH Clinical Center for Adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

38
Uterus, Endothelial, Testes, Pituitary, Brain, Monocytes, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 700)
# Title Authors Year
1
Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. ( 29304094 )
2018
2
Transvaginal Elastosonography as an Imaging Technique for Diagnosing Adenomyosis. ( 29320956 )
2018
3
Effect of pretreatment with gonadotropin-releasing hormone analog GnRH-I+ on high-intensity focused ultrasound ablation for diffuse adenomyosis: a preliminary study. ( 29447020 )
2018
4
Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options. ( 29402199 )
2018
5
Re: A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study Is the cost-effectiveness of HIFU for adenomyosis and fibroids feasible? ( 29405542 )
2018
6
Operation, hormone therapy and recovery of the patients with severe forms of adenomyosis. ( 29447009 )
2018
7
A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. ( 29344938 )
2018
8
Re: Pregnancy outcomes in patients with uterine fibroids treated with ultrasound-guided high-intensity focused ultrasound Is the noninvasive nature of HIFU ablation for uterine fibroids and adenomyosis setting patients up for future operative delivery? ( 29405613 )
2018
9
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
10
Anterior Focal Adenomyosis and Bladder Deep Infiltrative: is There a Link? ( 29432902 )
2018
11
ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis. ( 29409901 )
2018
12
Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis. ( 29434812 )
2018
13
Reproductive Outcomes after Fertility-Sparing Surgery for Focal and Diffuse Adenomyosis: a Systematic Review. ( 29305234 )
2018
14
The Risk of Preterm Births Among Pregnant Women With Adenomyosis. ( 29363150 )
2018
15
Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. ( 27792415 )
2017
16
Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. ( 27678100 )
2017
17
From Clinical Symptoms to MR Imaging: Diagnostic Steps in Adenomyosis. ( 29349064 )
2017
18
Unique Learning System for Uterine Artery Embolization for Symptomatic Myoma and Adenomyosis for Obstetrician-Gynecologists in Cooperation with Interventional Radiologists: Evaluation of UAE From the Point of View of Gynecologists Who Perform UAE. ( 28807810 )
2017
19
Berberine inhibits the LPS-induced proliferation and inflammatory response of stromal cells of adenomyosis tissues mediated by the LPS/TLR4 signaling pathway. ( 29285168 )
2017
20
Complications and outcomes of pregnant women with adenomyosis in Japan. ( 29259486 )
2017
21
Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study. ( 28856862 )
2017
22
Treatment of cornual pregnancy in a patient with adenomyosis by high-intensity focused ultrasound (HIFU) ablation: A case report. ( 29310371 )
2017
23
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. ( 29266553 )
2017
24
Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. ( 27986572 )
2017
25
A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. ( 28856866 )
2017
26
Effects of adenomyosis on inA vitro fertilization treatment outcomes: a meta-analysis. ( 28865548 )
2017
27
Immune-inflammatory predictors of the pelvic pain syndrome associated with adenomyosis. ( 29264987 )
2017
28
Concomitant use of transvaginal sonography and Doppler indices improve diagnosis of adenomyosis. ( 28766365 )
2017
29
Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: A case series. ( 29069006 )
2017
30
Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. ( 28864044 )
2017
31
T2 relaxometry mapping in demonstrating layered uterine architecture: parameter optimisation and utility in endometrial carcinoma and adenomyosis: A feasibility study. ( 28936889 )
2017
32
Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis. ( 28817677 )
2017
33
Title: Hysteroscopic Removal of Retained Products of Conception Implanted Over a Focal Area of Adenomyosis. a Case Report. ( 28939480 )
2017
34
The Expression of Toll-like receptors in eutopic and ectopic endometrium and its implication in the inflammatory pathogenesis of adenomyosis. ( 28779087 )
2017
35
The impact of adenomyosis on the outcome of IVF-embryo transfer. ( 28802706 )
2017
36
Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. ( 28911934 )
2017
37
Rhein ameliorates adenomyosis by inhibiting NF-I_B and I^-Catenin signaling pathway. ( 28763746 )
2017
38
Changes in anti-mA1llerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. ( 28856867 )
2017
39
A Rare Case of Intramural MA1llerian Adenosarcoma Arising from Adenomyosis of the Uterus. ( 28741605 )
2017
40
Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis. ( 28762845 )
2017
41
Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. ( 28069193 )
2017
42
The effect of exercise on high-intensity focused ultrasound treatment efficacy in uterine fibroids and adenomyosis: a retrospective study. ( 28856860 )
2017
43
Immunohistochemical Parameters of Musashi-1 in Nodular and Diffuse Adenomyosis. ( 28853072 )
2017
44
The Role of Hysteroscopy in the Diagnosis and Treatment of Adenomyosis. ( 28852646 )
2017
45
Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. ( 28927080 )
2017
46
Quercetin alleviates generalized hyperalgesia in mice with induced adenomyosis. ( 28849202 )
2017
47
Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. ( 27724926 )
2016
48
Expression of GRIM-19 inA adenomyosis and its possible roleA in pathogenesis. ( 26769301 )
2016
49
Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia. ( 27543913 )
2016
50
Immunohistochemical expression pattern of metastasis suppressor KISS-1 protein in adenomyosis lesions and normal endometrium. ( 27940396 )
2016

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 ESR1 MMP1 MMP2 MMP9 NGF PTGS2
2
Show member pathways
13.2 MMP1 MMP2 MMP9 PRL PTGS2 VEGFA
3
Show member pathways
13.19 MMP1 MMP2 MMP9 SPP1 VEGFA
4
Show member pathways
12.83 NGF PRL PTGS2 SPP1 VEGFA
5
Show member pathways
12.6 MMP1 MMP2 MMP9 SPP1 TIMP2
6 12.6 ESR1 MMP1 MMP2 MMP9 PTGS2 VEGFA
7
Show member pathways
12.41 ESR1 MMP1 MMP2 MMP9 VEGFA
8 12.18 ESR1 MMP2 MMP9 VEGFA
9
Show member pathways
12.06 MMP1 MMP2 MMP9 SPP1
10 12.01 ESR1 MMP1 VEGFA
11 11.96 MMP2 MMP9 VEGFA
12
Show member pathways
11.83 ESR1 PGR PRL
13 11.77 MMP1 MMP2 MMP9 PTGS2 VEGFA
14
Show member pathways
11.73 MMP1 MMP2 MMP9 TIMP2
15 11.61 MMP2 MMP9 PTGS2 TIMP2
16 11.59 MMP9 SPP1 VEGFA
17 11.57 MMP2 MMP9 SPP1
18 11.52 MMP9 PTGS2 VEGFA
19 11.49 MMP1 MMP2 MMP9 VEGFA
20 11.45 MMP1 PTGS2 VEGFA
21 11.42 ESR1 PTGS2 VEGFA
22 11.41 MMP1 MMP2 MMP9 PTGS2 VEGFA
23
Show member pathways
11.37 MMP2 MMP9 SPP1
24 11.34 MMP1 MMP2 MMP9 TIMP2
25 11.29 MMP1 MMP9 TIMP2
26 11.22 MMP1 MMP2 MMP9
27 11.07 ESR1 MMP2 MMP9
28 11.06 MMP9 TIMP2
29 11.01 MMP2 MMP9
30 11.01 MMP9 TIMP2 VEGFA
31 10.96 MMP1 MMP2
32 10.91 MMP1 VEGFA
33 10.86 MMP1 MMP9
34
Show member pathways
10.82 MMP1 MMP2 MMP9 PTGS2 VEGFA

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 MMP1 MMP2 MMP9 NGF PRL SPP1
2 extracellular matrix GO:0031012 9.46 MMP1 MMP2 MMP9 TIMP2
3 proteinaceous extracellular matrix GO:0005578 9.02 MMP1 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.85 NGF PRL SPP1 VEGFA
2 cellular protein metabolic process GO:0044267 9.62 MMP1 MMP2 PRL SPP1
3 response to estradiol GO:0032355 9.61 ESR1 OXTR PTGS2
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.58 NGF PTGS2 VEGFA
5 endodermal cell differentiation GO:0035987 9.57 MMP2 MMP9
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 MMP2 MMP9
7 decidualization GO:0046697 9.54 PTGS2 SPP1
8 collagen catabolic process GO:0030574 9.54 MMP1 MMP2 MMP9
9 response to vitamin D GO:0033280 9.52 PTGS2 SPP1
10 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.51 OXTR PTGS2
11 mammary gland alveolus development GO:0060749 9.49 ESR1 VEGFA
12 macrophage differentiation GO:0030225 9.48 MMP9 VEGFA
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.46 PTGS2 VEGFA
14 response to cytokine GO:0034097 9.43 OXTR PTGS2 TIMP2
15 lactation GO:0007595 9.33 OXTR PRL VEGFA
16 embryo implantation GO:0007566 9.26 MMP2 MMP9 PTGS2 SPP1
17 extracellular matrix disassembly GO:0022617 9.02 MMP1 MMP2 MMP9 SPP1 TIMP2

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metallopeptidase activity GO:0008237 9.43 MMP1 MMP2 MMP9
2 extracellular matrix binding GO:0050840 9.37 SPP1 VEGFA
3 steroid binding GO:0005496 9.32 ESR1 PGR
4 metalloendopeptidase inhibitor activity GO:0008191 9.16 NGF TIMP2
5 metalloendopeptidase activity GO:0004222 9.13 MMP1 MMP2 MMP9
6 zinc ion binding GO:0008270 9.1 ESR1 MMP1 MMP2 MMP9 PGR TIMP2

Sources for Adenomyosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....